More Company News

Mereo BioPharma

Positive Type B end of Phase II FDA feedback & outlines Phase III paediatric study
28 Feb 2020Read More

Mereo BioPharma

$3m investment from new US Institutional Investor
19 Feb 2020Read More

Mereo BioPharma

Agreement with Novartis and Aspire Capital Fund
10 Feb 2020Read More

Mereo BioPharma

Additional positive data from Phase 2b ASTEROID study
14 Jan 2020Read More

Mereo BioPharma

Mereo and Oncologie enter global licensing agreement for navicixizumab
13 Jan 2020Read More

Mereo BioPharma

Phase 2b ASTEROID study data in adults with osteogenesis imperfecta
11 Nov 2019Read More

Mereo BioPharma

FDA Fast Track Designation for Navicixizumab
07 Oct 2019Read More

Mereo BioPharma

H119 interims and corporate update
17 Sep 2019Read More

Mereo BioPharma

Setrusumab Phase IIb data to be presented at ASBMR 2019 meeting
04 Sep 2019Read More

Mereo BioPharma

Appointment of Head of Pharmaceutical Development
16 Jul 2019Read More

1 2 3
Return to Mereo BioPharma
© 2019-20 Trinity Delta. All rights reserved. Trinity Delta is regulated by the Financial Conduct Authority (Reference number: 725161).